Gilead Sciences Inc. (GILD)
If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names
When I think of biotech stocks, I imagine volatile share prices and plenty of red ink. I also think of big-time shareholder returns for the industry's winners.
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Want $3,000 In Passive Income? Invest $51,000 in These 3 High-Yield Dividend Plays
Dividend stocks can deliver both reliable income and substantial capital appreciation over long periods of time. Investing $51,000 across these three dividend-paying options could yield about $3,000 in yearly income.
Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $71.64, denoting a +1.17% change from the preceding trading day.
3 Underappreciated Stocks About to Break Their Chains
As investors buy from tech giants like Nvidia, many other compelling opportunities exist for those looking for growth. Driven by innovation, revenue growth, and an enviable market position, each of these 3 underappreciated stocks offers investors a unique opportunity for profitability.
Why Gilead Sciences (GILD) Outpaced the Stock Market Today
The latest trading day saw Gilead Sciences (GILD) settling at $68.75, representing a +1.46% change from its previous close.
Gilead Gets Analyst Upgrade on 'Outstanding' HIV Treatment Data
Gilead Sciences (GILD) shares climbed in intraday trading Monday after Raymond James analysts upgraded the drug developer to “outperform” from “market perform.”
Gilead (GILD) Loses 17.6% YTD: How Should You Play the Stock?
While Gilead (GILD) has been reeling under pressure year to date due to pipeline setbacks, holding on to this biotech giant will be prudent at current levels.
Analyst: Science Stock Sports Long-Term Support
Shares of drugmaker Gilead Sciences, Inc. (NASDAQ:GILD) are up 2% in pre-market trading, after Raymond James upgraded the stock to "outperform" from "market perform.
Gilead Records Positive Phase III Results In HIV
Gilead Sciences reports positive Phase III trial results for lenacapavir, showing zero incident cases of HIV infection in the treatment group. Results suggest the potential for lenacapavir to revolutionize HIV prevention and treatment, leading to market expansion and creating shareholder value. Gilead's diversified revenue streams from HIV, liver disease, COVID-19, and oncology products position the company for continued growth and success.
GILD Stock Today: Why A Broken Wing Butterfly Might Make Money In Gilead Sciences Stock
Support for Gilead shares sits near 57.
Gilead (GILD) Up as Twice-Yearly HIV Shot Prevents Infection
Gilead's (GILD) twice-yearly, subcutaneous lenacapavir has demonstrated its potential as a new tool to help prevent HIV infections with zero infections and 100% efficacy. Shares gain.
